Condition: Early Breast Cancer · Sponsor: Novartis Pharmaceuticals
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical practice patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, IIB, and a subset of Stage IIA Early Breast Cancer (EBC).
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Always discuss trial participation with your own doctor first.
| Central Alabama Research | Birmingham, Alabama, United States | Recruiting |
| Alaska Oncology and Hematology LLC | Anchorage, Alaska, United States | Recruiting |
| Western Reg MC-COH Phoenix | Goodyear, Arizona, United States | Recruiting |
| CARTI Cancer Center | Little Rock, Arkansas, United States | Recruiting |
| Beverly Hills Cancer Center | Beverly Hills, California, United States | Recruiting |
| Onco Inst of Hope and Innovation | Cerritos, California, United States | Recruiting |
| City of Hope National Medical | Duarte, California, United States | Recruiting |
| Providence Medical Foundation | Fullerton, California, United States | Recruiting |
| Los Angeles Cancer Network Good Samaritan | Los Angeles, California, United States | Recruiting |
| El Camino Hospital | Mountain View, California, United States | Recruiting |
| Palo Alto Medical Foundation | Mountain View, California, United States | Recruiting |
| UC Irvine Medical Center | Orange, California, United States | Recruiting |
+ 217 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05827081